1.75 semaglutide GLP-1 Wegovy (semaglutide) Injector 1.7 mg/0.75 mL Wegovy (semaglutide) Injector 1.7 mg/0.75

Patients with diabetes mellitus taking WEGOVY in combination with insulin or an insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia

It is a reasonable scientific curiosity, not a reason to fast and certainly not a reason to push fasts longer than feels good

Avoid smoking: Smoking weakens the protective lining of the stomach, making it more vulnerable to acid and inflammation

doi: 10.1007/s13300-014-0064-0

Wegovy highlights of prescribing information, Novo Nordisk (2024) The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy, Scientific Reports (2024) Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study, Frontiers in Pharmacology (2022) Most GLP-1 medications correlated with a lower likelihood of anxiety and depression diagnoses, Epic Research (2024) Dopamine release in the midbrain promotes anxiety, Biological Psychology (2021) Dopamine primes the brain for enhanced vigilance, MIT News (2018) Why your cardiologist may prescribe semaglutide (Wegovy), Yale Medicine (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice